Intech Investment Management LLC Buys New Shares in Vera Therapeutics, Inc. (NASDAQ:VERA)

Intech Investment Management LLC bought a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 10,737 shares of the company's stock, valued at approximately $475,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in Vera Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company's stock valued at $86,000 after acquiring an additional 350 shares during the last quarter. Arizona State Retirement System raised its stake in Vera Therapeutics by 14.4% during the second quarter. Arizona State Retirement System now owns 9,907 shares of the company's stock valued at $358,000 after buying an additional 1,250 shares in the last quarter. Ensign Peak Advisors Inc grew its position in shares of Vera Therapeutics by 13.5% in the 2nd quarter. Ensign Peak Advisors Inc now owns 11,750 shares of the company's stock worth $425,000 after acquiring an additional 1,400 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Vera Therapeutics by 30.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company's stock valued at $272,000 after acquiring an additional 1,737 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its stake in Vera Therapeutics by 19.0% during the third quarter. Handelsbanken Fonder AB now owns 13,800 shares of the company's stock worth $610,000 after purchasing an additional 2,200 shares during the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Vera Therapeutics

In related news, Director Beth C. Seidenberg sold 15,000 shares of Vera Therapeutics stock in a transaction on Monday, October 28th. The stock was sold at an average price of $48.03, for a total transaction of $720,450.00. Following the completion of the sale, the director now owns 131,553 shares of the company's stock, valued at approximately $6,318,490.59. This trade represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marshall Fordyce sold 23,125 shares of the firm's stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $46.05, for a total transaction of $1,064,906.25. Following the transaction, the chief executive officer now owns 307,972 shares in the company, valued at $14,182,110.60. This represents a 6.98 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 89,927 shares of company stock valued at $3,800,796. Company insiders own 21.70% of the company's stock.

Vera Therapeutics Price Performance

NASDAQ:VERA traded down $0.17 during trading hours on Tuesday, reaching $49.38. 345,445 shares of the company's stock were exchanged, compared to its average volume of 893,052. The company has a market capitalization of $3.13 billion, a P/E ratio of -18.92 and a beta of 1.08. Vera Therapeutics, Inc. has a 12 month low of $13.09 and a 12 month high of $51.61. The business's 50-day simple moving average is $44.31 and its two-hundred day simple moving average is $39.80. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Sell-side analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VERA has been the subject of several recent research reports. Guggenheim upped their target price on Vera Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a report on Monday, October 28th. JPMorgan Chase & Co. upped their price objective on Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Wedbush boosted their price target on shares of Vera Therapeutics from $30.00 to $38.00 and gave the company a "neutral" rating in a report on Friday, November 8th. Wells Fargo & Company began coverage on shares of Vera Therapeutics in a report on Thursday, November 21st. They issued an "overweight" rating and a $70.00 price objective on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $107.00 target price on shares of Vera Therapeutics in a research report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $59.22.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.